|
1
|
Raisz LG: Pathogenesis of osteoporosis:
concepts, conflicts, and prospects. J Clin Invest. 115:3318–3325.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Reginster JY and Burlet N: Osteoporosis: a
still increasing prevalence. Bone. 38 (Suppl 1):S4–S9. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Centrella M and McCarthy TL: Estrogen
receptor dependent gene expression by osteoblasts - direct,
indirect, circumspect, and speculative effects. Steroids.
77:174–184. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bilezikian JP, Raisz LG and Martin TJ:
Principles of bone biologyEstrogens and Progestins. Turner RT,
Rickard DJ, Iwaniec UT and Spelsberg TC: 3rd. Elsevier; Amsterdam:
pp. 855–885. 2008
|
|
5
|
Bradford PG, Gerace KV, Roland RL and
Chrzan BG: Estrogen regulation of apoptosis in osteoblasts. Physiol
Behav. 99:181–185. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Howlett AC: The cannabinoid receptors.
Prostaglandins Other Lipid Mediat. 68–69:619–631. 2002. View Article : Google Scholar
|
|
7
|
Whyte LS, Ryberg E, Sims NA, Ridge SA,
Mackie K, Greasley PJ, Ross RA and Rogers MJ: The putative
cannabinoid receptor GPR55 affects osteoclast function in vitro and
bone mass in vivo. Proc Natl Acad Sci USA. 106:16511–16516. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
van der Stelt M, Trevisani M, Vellani V,
De Petrocellis L, Schiano Moriello A, Campi B, McNaughton P, et al:
Anandamide acts as an intracellular messenger amplifying
Ca2+ influx via TRPV1 channels. EMBO J. 24:3026–3037.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Julien B, Grenard P, Teixeira-Clerc F, Van
Nhieu JT, Li L, Karsak M, Zimmer A, Mallat A and Lotersztajn S:
Antifibrogenic role of the cannabinoid receptor CB2 in the liver.
Gastroenterology. 128:742–755. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Steffens S, Veillard NR, Arnaud C, Pelli
G, Burger F, Staub C, Karsak M, Zimmer A, Frossard JL and Mach F:
Low dose oral cannabinoid therapy reduces progression of
atherosclerosis in mice. Nature. 434:782–786. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wright K, Rooney N, Feeney M, Tate J,
Robertson D, Welham M and Ward S: Differential expression of
cannabinoid receptors in the human colon: cannabinoids promote
epithelial wound healing. Gastroenterology. 129:437–453. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Idris AI, van't Hof RJ, Greig IR, Ridge
SA, Baker D, Ross RA and Ralston SH: Regulation of bone mass, bone
loss and osteoclast activity by cannabinoid receptors. Nat Med.
11:774–779. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ofek O, Karsak M, Leclerc N, Fogel M,
Frenkel B, Wright K, Tam J, Attar-Namdar M, Kram V, Shohami E, et
al: Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc
Natl Acad Sci USA. 103:696–701. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Whyte LS, Ford L, Ridge SA, Cameron GA,
Rogers MJ and Ross RA: Cannabinoids and bone: endocannabinoids
modulate human osteoclast function in vitro. Br J Pharmacol.
165:2584–2597. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hanus L, Breuer A, Tchilibon S, Shiloah S,
Goldenberg D, Horowitz M, Pertwee RG, Ross RA, Mechoulam R and
Fride E: HU-308: a specific agonist for CB2, a peripheral
cannabinoid receptor. Proc Natl Acad Sci USA. 96:14228–14233. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wartmann M, Campbell D, Subramanian A,
Burstein SH and Davis RJ: The MAP kinase signal transduction
pathway is activated by the endogenous cannabinoid anandamide. FEBS
Lett. 359:133–136. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Melck D, Rueda D, Galve-Roperh I, De
Petrocellis L, Guzman M and Di Marzo V: Involvement of the
cAMP/protein kinase A pathway and of mitogen-activated protein
kinase in the anti-proliferative effects of anandamide in human
breast cancer cells. FEBS Lett. 463:235–240. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu J, Gao B, Mirshahi F, Sanyal AJ,
Khanolkar AD, Makriyannis A and Kunos G: Functional CB1 cannabinoid
receptors in human vascular endothelial cells. Biochem J.
346:835–840. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Derkinderen P, Ledent C, Parmentier M and
Girault JA: Cannabinoids activate p38 mitogen-activated protein
kinases through CB1 receptors in hippocampus. J Neurochem.
77:957–960. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rueda D, Galve-Roperh I, Haro A and Guzmán
M: The CB1 cannabinoid receptor is coupled to the activation of
c-Jun N-terminal kinase. Mol Pharmacol. 58:814–820. 2000.PubMed/NCBI
|
|
21
|
Mombouli JV, Schaeffer G, Holzmann S,
Kostner GM and Graier WF: Anandamide-induced mobilization of
cytosolic Ca2+ in endothelial cells. Br J Pharmacol.
126:1593–1600. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rossi F, Siniscalco D, Luongo L, De
Petrocellis L, Bellini G, Petrosino S, Torella M, Santoro C, Nobili
B, Perrotta S, et al: The endovanilloid/endocannabinoid system in
human osteoclasts: possible involvement in bone formation and
resorption. Bone. 44:476–484. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rossi F, Bellini G, Luongo L, Torella M,
Mancusi S, De Petrocellis L, Petrosino S, Siniscalco D, Orlando P,
Scafuro M, et al: The endovanilloid/endocannabinoid system: a new
potential target for osteoporosis therapy. Bone. 48:997–1007. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rossi F, Bellini G, Luongo L, Mancusi S,
Torella M, Tortora C, Manzo I, Guida F, Nobili B, de Novellis V and
Maione S: The 17-beta-oestradiol inhibits osteoclast activity by
increasing the cannabinoid CB2 receptor expression. Pharmacol Res.
68:7–15. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu SF, Wang ZX, Yuan YE, Bing SM, Zhang
BZ, Wu JZ, Wu YE and Peng XY: Hormone changes during the menstrual
cycle of Chinese women. J Reprod Fertil. 76:43–52. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kousteni S, Chen JR, Bellido T, Han L, Ali
AA, O'Brien CA, Plotkin L, Fu Q, Mancino AT, Wen Y, et al: Reversal
of bone loss in mice by nongenotropic signaling of sex steroids.
Science. 298:843–846. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kumar P and Song ZH: Identification of
raloxifene as a novel CB2 inverse agonist. Biochem Biophys Res
Commun. 435:76–81. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kumar P and Song ZH: CB2 cannabinoid
receptor is a novel target for third-generation selective estrogen
receptor modulators bazedoxifene and lasofoxifene. Biochem Biophys
Res Commun. 443:144–149. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Idris AI, Sophocleous A, Landao-Bassonga
E, van't Hof RJ and Ralston SH: Regulation of bone mass, osteoclast
function, and ovariectomy-induced bone loss by the type 2
cannabinoid receptor. Endocrinology. 149:5619–5626. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Horst-Sikorska W and Wawrzyniak A: The
role of hormonal therapy in osteoporosis. Endokrynol Pol. 62:61–64.
2011.PubMed/NCBI
|
|
31
|
Ofek O, Attar-Namdar M, Kram V,
Dvir-Ginzberg M, Mechoulam R, Zimmer A, Frenkel B, Shohami E and
Bab I: CB2 cannabinoid receptor targets mitogenic Gi protein-cyclin
D1 axis in osteoblasts. J Bone Miner Res. 26:308–316. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sophocleous A, Landao-Bassonga E, Van't
Hof RJ, Idris AI and Ralston SH: The type 2 cannabinoid receptor
regulates bone mass and ovariectomy-induced bone loss by affecting
osteoblast differentiation and bone formation. Endocrinology.
152:2141–2149. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chlebowski RT, Anderson GL, Gass M, Lane
DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto
GE, et al: Estrogen plus progestin and breast cancer incidence and
mortality in postmenopausal women. JAMA. 304:1684–1692. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lépine J, Audet-Walsh E, Grégoire J, Têtu
B, Plante M, Ménard V, Ayotte P, Brisson J, Caron P, Villeneuve L,
et al: Circulating estrogens in endometrial cancer cases and their
relationship with tissular expression of key estrogen biosynthesis
and metabolic pathways. J Clin Endocrinol Metab. 95:2689–2698.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Guida M, Ligresti A, De Filippis D,
D'Amico A, Petrosino S, Cipriano M, Bifulco G, Simonetti S, Orlando
P, Insabato L, et al: The levels of the endocannabinoid receptor
CB2 and its ligand 2-arachidonoylglycerol are elevated in
endometrial carcinoma. Endocrinology. 151:921–928. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Qamri Z, Preet A, Nasser MW, Bass CE,
Leone G, Barsky SH and Ganju RK: Synthetic cannabinoid receptor
agonists inhibit tumor growth and metastasis of breast cancer. Mol
Cancer Ther. 8:3117–3129. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lagneux C and Lamontagne D: Involvement of
cannabinoids in the cardioprotection induced by lipopolysaccharide.
Br J Pharmacol. 132:793–796. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Odan M, Ishizuka N, Hiramatsu Y, Inagaki
M, Hashizume H, Fujii Y, Mitsumori S, Morioka Y, Soga M, Deguchi M,
et al: Discovery of S-777469: an orally available CB2 agonist as an
antipruritic agent. Bioorg Med Chem Lett. 22:2803–2806. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rinaldi-Carmona M, Barth F, Millan J,
Derocq JM, Casellas P, Congy C, Oustric D, Sarran M, Bouaboula M,
Calandra B, et al: SR 144528, the first potent and selective
antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther.
284:644–650. 1998.PubMed/NCBI
|
